Advances in Personalized Medicine and Your Future Health Experience
In the very near future, you may visit your doctor and receive a drug therapy that was customized just for you based on your DNA, metabolism, and lifestyle. Advances in key technologies, including decoding the human genome (DNA), artificial intelligence (AI), and health information, are the catalysts for the rapidly accelerating field of personalized medicine.
5:30: Registration, Networking, food and drinks
7:30: Audience Q & A
8:00: Program Concludes, Networking, Coffee & Dessert until 8:30
Navid Alipour, JD (Moderator)
Co-founder and Managing Partner, Analytics Ventures
Navid Alipour is Co-founder and Managing Partner at Analytics Ventures, a Venture Formation Fund focused on starting new ventures with artificial intelligence and machine learning at their core.
Prior to co-founding Analytics Ventures, he founded La Costa Investment Group, making investments in startups nationally. Through the founding of multiple Artificial Intelligence(AI) based companies like CureMetrix and CureMatch, Navid is a long-time entrepreneur in the AI space, and looks to address the need between angel investors and big venture capital funds. He has a passion for finding scientists and academics who are domain experts in their respective fields, and helping them turn their research into viable businesses, helping build companies from inception.
CEO and Co-founder, Luna PBC, LunaDNA
Bob Kain is a renowned pioneer in the field of genomics, spending most of his career growing Illumina, Inc. pre-IPO from 30 employees with no revenue, to a burgeoning workforce of over 3,000 employees and $1.4B in revenue. Bob came out of retirement following a 15+ year career as the chief engineering officer at Illumina to co-found LunaDNA, a community-owned health and DNA data platform and currently serves as the CEO of LunaPBC, a Public Benefit Corporation who manages the LunaDNA platform. He realized the true potential and growing popularity of direct-to-consumer genomic testing and envisioned how this data could be used to disrupt the traditional approach to medical research.
Stephane Richard, Ph.D.
COO, CureMatch, Inc.
Involved with the company development since day one, Stephane is COO of CureMatch. With over fifteen years of international business development experience, Stephane brings to CureMatch his experience with the biotech industry, strategy, management and an exceptional network of collaborators. Since 2006, Stephane has been the Founder & President of French BioBeach, an organization promoting business between Southern California and European Life science groups. As an author of 17 scientific papers and 6 patents, Stephane received a Ph.D. in biophysics from the University Joseph Fourier in Grenoble, France. He has served as a scientist at Sapphire Energy, the Salk Institute for Biological Studies, and visiting scientist at the Sanford-Burnham Prebys Medical Discovery Institute, before holding managerial positions in biotech.
Co-founder and CEO, EpigenetisRx
EpigeneticsRx is a one-stop digital destination to all the tools Physicians need for precise, personalized, prevention based on genetics. EpigeneticsRx’s secure platform transforms “omic” data into actionable health plans – reducing the total cost of care and improving health outcomes.
Deb has dedicated her career to measuring and improving healthcare outcomes. Her expertise is leveraging technology to deliver personalized, integrative medicine. Deb founded her first preventative health care business in 1984 and has spent her career as both an entrepreneur and executive of public companies including Bank One and Imperial Bank. She co-founded La Vita Compounding Pharmacy in 2007. Collaborating with her business partner, physicians and strategic partners, Deb has grown La Vita to be one of the most respected and sought-after personalized medicine providers on the west coast.
CEO and Board Member, CureMetrix
CureMetrix is a healthcare technology company that develops artificial intelligence or AI-driven software for radiology. Driving AI solutions into the market requires management of complexities including global regulatory approval, channel development, and establishing medical credibility. Under Kevin’s leadership, CureMetrix launched the first FDA-cleared software in the U.S. that uses AI for mammography to help improve cancer survival rates worldwide.
Prior to that Kevin held a variety of C-level and leadership positions at product and consulting firms across a variety of industries. He has also led his own consulting company, Harris Consulting Group, helping clients focus on strategy, innovation, and execution. Prior to forming HCG, Kevin was CEO of SharePoint360 where he was responsible for transforming the company from an underperforming group of developers to a successful consulting and hosting firm. Kevin’s specialty is infusing operational elegance into companies that are looking for a path to sustained growth.
COMMUNITY PARTNER THIS MONTH